» Articles » PMID: 29119933

Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis

Overview
Date 2017 Nov 10
PMID 29119933
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cognitive impairment is one of the most important clinical features of neurodegenerative disorders including multiple sclerosis (MS). Conducted research shows that up to 65 percent of MS patients have cognitive deficits such as episodic memory, sustained attention, reduced verbal fluency; however, the cognitive MS domain is information processing speed. It is the first syndrome of cognitive dysfunction and the most widely affected in MS. Occasionally these impairments occur even before the appearance of physical symptoms.

Methods: Therefore, this review focused on the current status of our knowledge about possible methods of treatment cognitive impairment in MS patients including novel strategies. Research and online content was performed using Medline and EMBASE databases.

Results: The most recent research suggests that cognitive impairment is correlated with brain lesion volume and brain atrophy. The examination of the cognitive impairment is usually based on particular neuropsychological batteries. However, it can be not enough to make a precise diagnosis. This creates a demand to find markers that might be useful for identifying patients with risk of cognitive impairment at an early stage of the disease. Currently the most promising methods consist of neuroimaging indicators, such as diffusion tensor imaging, the magnetization transfer ratio, and N-acetyl aspartate levels. Diagnosis problems are strictly connected with treatment procedures. There are two main cognitive therapies: pharmacological (disease modifying drugs (DMD), symptomatic treatments) and non-pharmacological interventions that are focused on psychological and physical rehabilitation. Some trials have shown a positive association between physical activity and the cognitive function.

Conclusion: This article is an overview of the current state of knowledge related to cognition impairment treatment in MS. Additionally, novel strategies for cognitive impairments such as cryostimulation and other complementary methods are presented.

Citing Articles

Non-Pharmacological Treatments of Cognitive Impairment in Multiple Sclerosis: A Review.

Bossa M, Manocchio N, Argento O NeuroSci. 2024; 3(3):476-493.

PMID: 39483435 PMC: 11523695. DOI: 10.3390/neurosci3030034.


Impact of Cognitive and Psychological Functions in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional Study.

Yadav V, Hegde S, Netravathi M, Philip M, Cranberg L Ann Indian Acad Neurol. 2024; 27(5):530-536.

PMID: 39388406 PMC: 11575873. DOI: 10.4103/aian.aian_434_24.


The effect of atomoxetine on cognitive function in patients with multiple sclerosis.

Mohammadian Nejad E, Amouzadeh E, Kashipazha D, Shamsaei G, Cheraghian B Curr J Neurol. 2023; 22(3):149-154.

PMID: 38011451 PMC: 10626139. DOI: 10.18502/cjn.v22i3.13792.


Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Islam M, Alam S, Kundu S, Ahmed S, Sultana S, Patar A J Clin Med. 2023; 12(19).

PMID: 37834955 PMC: 10573670. DOI: 10.3390/jcm12196311.


Exploring the impact of exercise and essential amino acid plus cholecalciferol supplementation on physical fitness and body composition in multiple sclerosis: A case study.

Ispoglou T, Ferentinos P, Prokopidis K, Blake C, Aldrich L, Elia A Clin Case Rep. 2023; 11(6):e7548.

PMID: 37323260 PMC: 10264925. DOI: 10.1002/ccr3.7548.


References
1.
Krause M, Mahant N, Kotschet K, Fung V, Vagg D, Wong C . Dysexecutive behaviour following deep brain lesions--a different type of disconnection syndrome?. Cortex. 2011; 48(1):97-119. DOI: 10.1016/j.cortex.2011.03.014. View

2.
Foley J, Brandes D . Redefining functionality and treatment efficacy in multiple sclerosis. Neurology. 2009; 72(23 Suppl 5):S1-11. DOI: 10.1212/WNL.0b013e3181a99bc2. View

3.
Frischer J, Bramow S, Dal-Bianco A, Lucchinetti C, Rauschka H, Schmidbauer M . The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009; 132(Pt 5):1175-89. PMC: 2677799. DOI: 10.1093/brain/awp070. View

4.
Morel A, Bijak M, Miller E, Rywaniak J, Miller S, Saluk J . Relationship between the Increased Haemostatic Properties of Blood Platelets and Oxidative Stress Level in Multiple Sclerosis Patients with the Secondary Progressive Stage. Oxid Med Cell Longev. 2015; 2015:240918. PMC: 4429191. DOI: 10.1155/2015/240918. View

5.
Patti F, Morra V, Amato M, Trojano M, Bastianello S, Tola M . Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One. 2013; 8(8):e74111. PMC: 3796707. DOI: 10.1371/journal.pone.0074111. View